Up in smoke: the SRI case for marijuana (Citywire Selector)


Marijuana’s hip image is changing into something altogether more pedestrian thanks to its rising profile in medicine. Extracts of cannabis have been recommended for anorexia, pain relief and epilepsy. As the substance swaps the streets for the pharmacy shelves, some investors spy an opportunity.

In 2016 the medical marijuana market posted revenues of $6.3 billion, up from 30% the previous year. In 2017, two marijuana-focused ETFs were launched comprising stocks such as British firm GW Pharmaceuticals and Canada-based medical cannabis group Canopy Growth Corporation.

- Promotion -



Partner content

In the current economic environment, even the strongest companies will face challenges from the impact of the COVID-19 pandemic. Perhaps now more than ever, understanding the factors that could have a material impact on a company’s sustainability will play a role in investment decision-making.

NordSIP Insights

Most read this week

Stakeholders React to Proposed ESG Amendments to MIFID II

Stockholm (NordSIP) - In the latest step of the process of legislating a sustainable investment infrastructure for the European Union, the European Commission requested...